|
Office of Biotechnology Activities
|
National Institutes of Health - Office of Science Policy
|
| |
| RAC December 5, 2002 - Presentation Materials |
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Informed Consents for Clinical Trials Using Retroviral Vectors |
|
|
| |
James Childress, Ph.D., and Madison Powers, J.D., D.Phil., |
|
|
| |
Slides
|
|
| |
|
|
|
Requirements for Ethical Research |
|
|
| |
Dale Hammerschmidt, M.D., University of Minnesota |
|
|
| |
Slides
|
|
| |
|
|
|
Monitoring for Insertional Oncogenesis and Clonality of Hemotopoiesis after Gene Therapy |
|
|
| |
Kenneth Weinberg, M.D., USC School of Medicine/Children's Hospital of Los Angeles |
|
|
| |
Slides
|
|
| |
|
|
|
|
Discussion of Human Gene Transfer Protocol #0210-556 Entitled: |
|
|
| |
A Phase I, Open-Label, Dose-Escalation Trial Evaluating the Safety and Immunogenicity of Sequential Administration of Recombinant DNA and Adenovirus Expressing L523S Protein in Patients With Early-Stage Non-Small Cell Lung Cancer (NSCLC) |
|
|
| |
John J. Nemunaitis, M.D., US Oncology, Dallas, Texas |
|
|
| |
Slides
|
|
| |
|
|
|
ADJOURN |
|
| |
|
Top of Page |
| |
|
|
|
|
|
|